| Biomarker ID | 608 |
| PMID | 21400514 |
| Year | 2011 |
| Biomarker | miR-136-star; miR-145; miR-214; miR-221; miR-222; miR-302d-star; miR-378-star |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downregulated in PCa (Fold Change): miR-136-star(1.18 fold) ; miR-145(1.44 fold); miR-214(1.74 fold); miR-221(2.16 fold) ; miR-222(2.91 fold) ; miR-302d-star(1.13 fold); miR-378-star(1.30 fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(miR-101):- DNA binding; Gene expression (Transcription); Generic Transcription Pathway; RNA Polymerase II Transcription; DNA-binding transcription factor activity, RNA polymerase II-specific Pathways Include(miR-106a):- DNA-binding transcription factor activity, RNA polymerase II-specific ;Gene expression (Transcription); RNA Polymerase II Transcription; Generic Transcription Pathway; DNA-binding transcription factor activity Pathways Include(miRNA-141):- regulation of RNA metabolic process; Gene expression (Transcription); RNA Polymerase II Transcription; nuclear chromosome; DNA-binding transcription factor activity, RNA polymerase II-specific |
| Experiment | Prostate Cancer Vs Normal |
| Type of Biomarker | Diagnostic |
| Cohort | 20 matched tumor and normal tissue samples were measured. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | MiRNA microarrays |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Dataset |
| Technical Name | miR-136-star, miR-145, miR-214, miR-221, miR-222, miR-302d-star, miR-378-star |